Elander & the News
@ElanderNews
ITALY - A man Shot dead 2 of 3 robbers to defend his shop and wife and daughter who had both been tied up.
He’s been ordered to pay €280,000 to the criminals families and imprisoned for 17 YEARS!!!
The court decided he was a vigilante and the liberals called him a fascist 🤡
1:48 AM · Dec 7, 2023
·
https://twitter.com/ElanderNews/status/1732668356937839007
Thousands of tons of dead fish wash ashore in Japan - three months after the nation released treated Fukushima radioactive water into the sea
https://www.msn.com/en-us/news/world/thousands-of-tons-of-dead-fish-wash-ashore-in-japan-three-months-after-the-nation-released-treated-fukushima-radioactive-water-into-the-sea/ar-AA1lcUKG
Thousands of tons of dead fish have washed up on a beach in northern Japan, prompting speculation that the release of treated radioactive water from the Fukushima nuclear plant has wrought havoc on local ecosystems.
The sardines and some mackerel washed ashore in Hakodate on Japan's northernmost main island of Hokkaido on Thursday morning, creating an unsettling sliver blanket that covered almost a mile of shoreline.
An official announcement was devoid of any explanation for the phenomenon.
Takashi Fujioka, a Hakodate Fisheries Research Institute researcher, posited a number of theories as to why the fish could have died en-masse.
He said they may have become exhausted due to a lack of oxygen while moving in a densely packed school in shallow waters, or may have suddenly entered cold waters during their migration and succumbed to shock, he said.
There have been several recorded cases of similar phenomena springing up on several parts of Japan's coastline.
But this particular phenomenon occurred just three months after Japanese authorities began releasing treated radioactive water back into the sea - a move which angered its neighbours including China and South Korea.
China has since banned Japanese seafood and criticised the country as being 'extremely selfish and irresponsible', with the Chinese Communist Party's flagship newspaper The Global Times writing it could open 'Pandora's box' and trigger fears of a 'real-life Godzilla'.
South Korean protestors also attempted to enter the Japanese embassy in Seoul carrying banners which read 'The sea is not Japan's trash bin'.
The sardines and some mackerel washed ashore in Hakodate on Japan's northernmost main island of Hokkaido on Thursday morning
The phenomenon created an unsettling sliver blanket that covered almost a mile of shoreline
A closer look at TEPCO's Fukushima Daiichi Nuclear Power Plant in Okuma
Local residents observing the shoreline in Hakodate said they had never seen anything like it.
Some gathered the fish to sell or eat, prompting the town to urge residents not to consume the fish in a notice posted on its website,
The decomposing fish could lower oxygen levels in the water and affect the marine environment, Fujioka said.
'We don't know for sure under what circumstances these fish were washed up, so I do not recommend eating them,' he concluded.
In March 2011 the Fukushima power plant was wrecked after an earthquake and subsequent tsunami destroyed the plant's cooling systems, causing three reactors to melt.
Now, an undersea tunnel is being used to discharge the radioactive water treated by the Advanced Liquid Processing System, which uses a process called isotopic dilution to render the water less dangerous.
This process sees tritium - a less harmful radioactive isotope - added to the contaminated water which is subsequently mixed with 'clean seawater', diluting the concentration of more harmful substances.
Japanese officials maintain that the treated water is safe.
But critics say a lack of long-term data means it is impossible to say with certainty that tritium poses no threat to human health or the marine environment.
Greenpeace said the radiological risks had not been fully assessed and that the biological impacts of tritium 'have been ignored'.
Activists take part in a protest against Japan releasing treated radioactive water from the wrecked Fukushima nuclear power plant in Busan, South Korea
More South Korean protestors take to the streets complaining about toxic water treatment
The Fukushima power plant, pictured after being damaged, was crippled by an earthquake and tsunami in 2011
"worldwide catastrophe"- Xi Jinping
wormwood?
https://www.tellerreport.com/news/2023-11-17-xi-jinping-to-fumio-kishidafukushima-water-discharge-isa-source-of-concern-for-all-humanity-.r1OhwgHET.html
https://www.barrons.com/news/xi-warns-japan-pm-fukushima-water-release-affects-health-of-all-humankind-455fa2ea
https://www.iscaninfo.com/article/13845438/Xi-Jinping-pointed-out-the-harm-to-all-humanity-from-water-from-Fukushima
vidrel
https://petermcculloughmd.substack.com/p/rationale-for-nicotine-patch-in-treatment
Rationale for Nicotine Patch in Treatment of Long-COVID and Vaccine Injury Syndromes
Simple Intervention Provides Hope for Amelioration of Cognitive and Somatic Symptoms
PETER MCCULLOUGH, MD
In my practice, most patients with post-acute sequelae after SARS-CoV-2 infection and COVID-19 vaccination are on the McCullough Protocol Base Spike Detoxification. The word “base” is important because it signifies that in addition to triple therapy with nattokinase, bromelain, and curcumin, other drugs and interventions can be added to reduce the intensity and duration of symptoms while the root cause of the syndrome (Spike protein) is being cleared from the body.
Leitzke summarized the literature on post-acute sequelae being related to residual SARS-CoV-2 interactions with the ACE-2 receptor as well as nicotinic acetylcholine receptors (nAChR).
Changeux et al. (2020) recently proposed a ´nicotine hypothesis´, which implicates the propensity of SARSCoV-2 to not only bind to ACE2-receptors (ACE2R) but to nicotinic AChRs, as well (Changeux et al. 2020). Viral particles competing with acetylcholine for nAChR binding in order to enter the human body may lead to primary neuro infection (Changeux et al. 2020; Steardo et al. 2020). Furthermore, among the severe and fatal cases of COVID-19, the proportion of nicotine consumers was significantly lower than non-consumers of nicotine (Miyara, et al. 2020). Since nicotine may protect nAChRs from viral attachment, therapeutic nicotine application was proposed in the management of acute COVID-19 infections (Changeux et al. 2020). This argument is convincingly supported by the cohort study of Hippisley-Cox et al. (2020), with a total of 8.28 million participants (including 19,486 confirmed COVID-19 cases), showing lower odds for COVID-19 infection and COVID-19-related ICU stay in association with smoking (Hippisley-et al. 2020).
Nicotine binds to nAChR and works to competitively antagonize Spike protein while at the same time upregulating nAChR.
Wall Street CEOs try to convince senators that new capital rules will hurt Americans as well as banks
https://www.msn.com/en-us/money/markets/wall-street-ceos-try-to-convince-senators-that-new-capital-rules-will-hurt-americans-as-well-as-banks/ar-AA1l6yxF
The CEOs of eight banks sought to raise alarms over a sweeping set of higher standards known as the Basel 3 endgame.
"The rule would have predictable and harmful outcomes to the economy, markets, business of all sizes and American households," JPMorgan Chase CEO Jamie Dimon told lawmakers.
Democratic Sen. Sherrod Brown, chairman of the Senate Banking Committee, ripped the banks' lobbying efforts against the proposed rules.
Wall Street CEOs on Wednesday pushed back against proposed regulations aimed at raising the levels of capital they'll need to hold against future risks.
In prepared remarks and responses to lawmakers' questions during an annual Senate oversight hearing, the CEOs of eight banks sought to raise alarms over the impact of the changes. In July, U.S. regulators unveiled a sweeping set of higher standards governing banks known as the Basel 3 endgame.
"The rule would have predictable and harmful outcomes to the economy, markets, business of all sizes and American households," JPMorgan Chase CEO Jamie Dimon told lawmakers.
If unchanged, the regulations would raise capital requirements on the largest banks by about 25%, Dimon claimed.
The heads of America's largest banks, including JPMorgan, Bank of America and Goldman Sachs, are seeking to dull the impact of the new rules, which would affect all U.S. banks with at least $100 billion in assets and take until 2028 to be fully phased in. Raising the cost of capital would likely hurt the industry's profitability and growth prospects.
It would also likely help nonbank players including Apollo and Blackstone, which have gained market share in areas banks have receded from because of stricter regulations, including loans for mergers, buyouts and highly indebted corporations.
While all the major banks can comply with the rules as currently constructed, it wouldn't be without losers and winners, the CEOs testified.
Those who could be unintentionally harmed by the regulations include small business owners, mortgage customers, pensions and other investors, as well as rural and low-income customers, according to Dimon and the other executives.
"Mortgages and small business loans will be more expensive and harder to access, particularly for low- to moderate-income borrowers," Dimon said. "Savings for retirement or college will yield lower returns as costs rise for asset managers, money-market funds and pension funds."
With the rise in the cost of capital, government infrastructure projects will be more expensive to finance, making new hospitals, bridges and roads even costlier, Dimon added. Corporate clients will need to pay more to hedge the price of commodities, resulting in higher consumer costs, he said.
The changes would "increase the cost of borrowing for farmers in rural communities," Citigroup CEO Jane Fraser said. "It could impact them in terms of their mortgages, it could impact their credit cards. It could also importantly impact their cost of any borrowing that they do."
Finally, the CEOs warned that by heightening oversight on banks, regulators would push yet more financial activity to nonbank players — sometimes referred to as shadow banks — leaving regulators blind to those risks.
The tone of lawmakers' questioning during the three-hour hearing mostly hewed to partisan lines, with Democrats more skeptical of the executives and Republicans inquiring about potential harms to everyday Americans.
Sen. Sherrod Brown, an Ohio Democrat, opened the event by lambasting banks' lobbying efforts against the Basel 3 endgame.
p1
"You're going to say that cracking down on Wall Street is going to hurt working families, you're really going to claim that?" said Brown, who chairs the Senate Banking Committee. "The economic devastation of 2008 is what hurt working families, the uncertainty and the turmoil from the failure of Silicon Valley Bank hurt working families."
>monstrous
VACCINE IS SUSPECTED
"Police deaths and illnesses alarm, we want data"
https://lanuovabq.it/it/allarme-decessi-e-malori-in-polizia-vogliamo-i-dati
The police union Osa raises the alarm: "Too many deaths and illnesses in the Police, we have asked the general management for the data. A lot of officers tell us that they are sick after vaccination." And in Catanzaro, the Public Prosecutor authorizes the search for the correlation on a deceased 29-year-old policewoman.
Sudden illnesses and deaths in the Police are alarming the officers. On 17 November, the OSA (Autonomous Trade Union Organisation) trade union officially launched a study on the causes of deaths from suicide or sudden illness among uniformed workers.
Antonio Porto, national secretary of OSA, has long been fighting to bring out the problem of adverse events from vaccines among police officers. A battle that has paid off on his skin, also suffering a couple of suspensions for the vaccination cause, even if imposed within his union activity.
Osa, in fact, is among the drafters of the complaint relating to Aifa leaks and which is being investigated by the Rome Public Prosecutor's Office and which also sees the former Minister of Health Roberto Speranza and the former General Manager of Aifa Nicola Magrini under investigation for various crimes. In addition to this investigation - which is under suspicion of a request for dismissal which, however, if confirmed, has not yet been notified to the parties involved - OSA is also taking action to shed light on an increase in illnesses and unexplained deaths, perceived among operators.
"The study," reads the request sent to the Trade Union Relations Office of the Department of Public Security, "was necessary as there is a real alarm within the Police for the very high number of deaths that are beginning to be many, too many compared to previous years."
his speech writer, Elizabeth Clare Prophet, approves. kek!
>general flynn and elizabeth clare prophet
Historically, a Mason had to complete either the Scottish Rite or York Rite systems to be eligible for membership in the Shrine.
https://timesmachine.nytimes.com/timesmachine/1883/06/07/102828148.pdf
fuck Sawyer, He lied and facilitated the cover up of child trafficking in Tucson, AZ
>Ever question what NASA/Government says?
>It’s worthwhile doing so.
or what NASA does:
https://journalofethics.ama-assn.org/article/should-nasa-collect-astronauts-genetic-information-occupational-surveillance-and-research/2018-09#:~:text=The%20EO%20barred%20discrimination%20based%20on%20genetic%20information%2C,and%20mitigate%20the%20health%20consequences%20of%20space%20flight.
What Is the Genetic Information Nondiscrimination Act?
Anticipating the rapid development of genomics and its implications for both use and misuse, in February of 2000, President William J. Clinton signed Executive Order (EO) 13145, which prohibited genetic discrimination in the federal workplace. The EO barred discrimination based on genetic information, while allowing federal employers to conduct genetic testing for use in occupational surveillance and in other human research conducted under the Common Rule.1 Eight years later, in 2008, the passage of the Genetic Information Nondiscrimination Act (GINA) extended the EO’s protections beyond the federal government to the general public and beyond employment to health insurance.2 Ten years after the passage of GINA, theNational Aeronautics and Space Administration (NASA) has just begun to seriously engage with genomicsas a means to understand and mitigate the health consequences of space flight.
Genetic data collected as a part of NASA’s occupational surveillance must be properly safeguarded to ensure its storage and use in accordance with GINA and the Privacy Act.
As a part of occupational surveillance, GINA allows employers to collect genetic information to monitor biological effects of toxic substances in the workplace.
GINA’s rules do not limit the authority of a federal department or agency to conduct or sponsor occupational research or other health research under the Common Rule.8 Equal Employment Opportunity Commission (EEOC) federal regulations, which interpret GINA, state that GINA should be construed so that it does not “limit the authority of a Federal department or agency to conduct or sponsor occupational or other health research.”
FDA Approves First CRISPR Treatment in U.S.
https://time.com/6343853/fda-crispr-treatment-sickle-cell/
It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier first described a new way to edit genes, called CRISPR, in a scientific paper. The discovery is so game-changing that the pair earned the Nobel Prize in Chemistry in 2020 for how it could transform the way genetic diseases are treated. Now, on Dec. 8, the U.S. Food and Drug Administration (FDA) approved the very first treatment in the country based on the technology.
In the medical world, that’s lightning speed. “It’s incredible,” says Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley. “It’s so exciting to see how fast, and frankly how safely and effectively, this therapy is being rolled out in humans.”
The U.K. had already approved the CRISPR treatment, called exa-cel (brand name: Casgevy), from Vertex Pharmaceuticals and CRISPR Therapeutics (which was co-founded by Charpentier), to treat people with sickle cell disease and beta thalassemia. People with these conditions are born with genetically abnormal blood cells. In the case of sickle cell, the mutations in the gene coding for hemoglobin can cause blood cells to form a sickle shape, rather than a spherical one, and clog up small blood vessels, leading to potentially life-threatening episodes of pain and a higher risk of stroke. Patients with beta thalassemia develop anemia so severe that it can damage organs. Both conditions require lifelong and repeated blood transfusions. CRISPR can increase the population of healthy blood cells in both groups of patients. The FDA approved exa-cel for sickle cell disease, and will make a decision about treating beta thalassemia by March 2024.
The agency also approved another more traditional gene therapy for the disease as well: lova-cel (brand name: Lygenia) from bluebird bio, giving sickle cell patients two powerful new ways of controlling the debilitating and painful attacks that are the hallmark of their disease.
"Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited," said Dr. Nicole Verdun, director of the office of therapeutic products in the FDA's Center for Biologics Evaluation and Research, in a statement announcing the approvals.
How exa-cel and lova-cel work
CRISPR is an ideal therapy for these conditions since it involves editing mutated genes in a one-time treatment that could lead to a functional cure. Doctors extract blood stem cells, which produce the body’s entire population of blood and immune cells, from a person's bone marrow, then grow those cells in the lab. Then, they edit the genes in those cells to boost the production of fetal hemoglobin, which is able to carry more oxygen than adult hemoglobin but normally disappears after birth.
Researchers looked for ways to increase fetal hemoglobin concentration after they learned that about 10% of all people naturally continue to make fetal hemoglobin throughout their adult lives and remain healthy. Among them, people who also had sickle cell disease seemed to have milder forms. Their theory was that increasing the amount of fetal hemoglobin in the blood could help healthy blood cells outcompete the sickled versions and significantly cut down on the chances that the sickled cells would link together and block small vessels. That became the basis of exa-cel.
Exa-cel does this by using CRISPR to target the gene that shuts off fetal hemoglobin. “It’s like removing the stop sign and allowing traffic—in this case, fetal hemoglobin—to go forward down the road,” says Dr. Sharl Azar, medical director of the comprehensive sickle cell disease treatment center at Massachusetts General Hospital.
p1
Lova-cel uses a modified virus that can't cause disease to introduce a new gene for hemoglobin that mimics the healthy version, with an added anti-sickling feature. Sickled cells tend to form long, stiff chains that can clog vessels and trigger pain, but lova-cel's hemoglobin "breaks down the chain so they don't form the long rods anymore," says Rich Colvin, chief medical officer at bluebird. The end result is that patients have more healthy, unsickled blood cells so they cause fewer painful blockages.
The FDA's decision
In making its decision on exa-cel, the FDA reviewed a study of 31 patients with sickle cell disease who had experienced repeated blockages in their blood vessels. After getting exa-cel, 29 had no such attacks for a year. While it's not clear yet how long the effects will last, experts hope that these early results mean longer, and potentially life-long, freedom from hospital visits and painful episodes. For lova-cel, the agency looked at a study involving 32 patients; 28 did not experience any attacks during the two-year study period.
The agency also considered possible side effects. In the case of CRISPR, the most dangerous is off-target editing, in which CRISPR alters the wrong genes or alters genes that can prompt cells to start dividing out of control into a tumor. So far, patients who have received the therapy have not experienced these or other serious side effects. With lova-cel, one of the biggest concerns is where the gene for the healthy hemoglobin is inserted; Colvin says that studies so far show that the gene is inserted up to three times in a single cell, which does not appear to prompt the cell to start dividing abnormally. But “only time will tell whether we have actually done more harm than good by doing these genetic modifications,” says Dr. Markus Mapara, director of the adult bone-marrow transplant and cell-therapy program at NewYork-Presbyterian/Columbia, who has conducted several gene-therapy trials and has consulted for CRISPR Therapeutics. Verdun at the FDA said during a briefing that the agency asked both companies to follow patients for 15 years to document any potential long-term effects of the therapies, including cancers.
A one-time treatment, but an arduous road
As life-changing as both therapies can be, treatment is a grueling, months-long process. Both procedures involve nearly a year of tests and procedures, including an invasive bone marrow transplant. “It’s not for the faint of heart,” says Dr. Monica Bhatia, director of the pediatric stem-cell-transplant program at NewYork-Presbyterian/Columbia. To be eligible for either therapy, people need to be over 12 years old and have had repeated episodes of blockages due to sickle cell.
The first step is a series of exchange blood transfusions, in which some sickled cells are replaced with healthy cells. The outpatient procedure, which takes place over three to four months, temporarily reduces inflammation and the risk of blockages and attacks leading up to the treatment.
Once the level of sickled cells has dropped low enough, patients are hospitalized so doctors can collect enough stem cells from their bone marrow to be either edited with CRISPR or modified to make healthy hemoglobin, and reinfused back in the patients. Because the bone marrow in sickle cell patients isn’t as robust as that in healthy people, this could take several extraction cycles, and some patients may not even be able to produce enough to qualify for treatment, says Mapara.
If the doctors can recover enough stem cells, they are shipped to Vertex's and bluebird's labs, where scientists perform the CRISPR editing, which can take eight to 12 weeks, or the gene therapy so the cells can start producing healthy hemoglobin.
p2